Blog

The Royal College of Psychiatrists (RCPsych) have released a position statement on the efficacy and safety of psychedelics and related substances (PARS), in addition to updated clinical guidance surrounding research into these compounds and a framework for delivering assisted psychotherapy.

To date, there has been a lack of consensus in the field of psychedelic research regarding key terms. It is our hope that development of this lexicon can aid in translating findings across various research groups and improve clarity and precision in our communications with each other and the general public.

Facing a terminal diagnosis is one of life’s most difficult challenges. Beyond the physical burden of illness, patients often experience anxiety, depression, insomnia, and existential distress – a sense of suffering that touches mind and body alike.

Psychedelic-assisted therapy (PAT) is an emerging treatment that combines pharmacotherapeutic dosing sessions with psychotherapy. Despite limited regulatory approval, treatment seekers can access PAT through various avenues, including ketamine treatment centers and “supported adult use” psilocybin centers in the US, drug tourism, “underground” therapy, and participation in clinical trials.

For the 2nd year in a row, the Drug Science team was invited to host a discussion around psychedelics at We Out Here Festival, which is held in Wimborne St Giles, Dorset.

Drug Science responded to the Advisory Council on the Misuse of Drugs’ (ACMD’s) call on Ketamine use, harms and interventions. We hope that our evidence can help to develop rational debate, policy making and scheduling about Ketamine.

Germany has recently taken a landmark step by introducing compassionate access to psilocybin for patients with treatment-resistant depression (TRD), marking the first such programme in the European Union.

Last week, the Ministry of Health quietly marked a historic milestone: it granted a license to Christchurch-based psychiatrist Professor Cameron Lacey to prescribe psilocybin for treatment-resistant depression. This is the first time the psychedelic compound will be legally prescribed in New Zealand outside of a clinical trial.

The reemergence of psychedelic therapy presents a rare opportunity to reimagine psychiatry’s epistemic foundations. Rather than simply repackaging these substances within a biomedical framework, this moment should prompt critical interrogation of the assumptions underlying dominant models of mental illness and healing.

Current regulation frameworks for medicines struggle to address the combination of pharmacological and psychotherapeutic elements in psychedelic therapy.

As our societies grapple with environmental and mental health challenges, investigating potential avenues for restoring relations with nature is more important than ever.

The increasing incidence of opioid dependence linked to the consumption of unwashed poppy seeds (UPSs) is an emerging public health concern.

Last week, the Ukrainian Ministry of Health took an important step toward enabling scientific research with psychedelics.

When the email invite came I thought it was a hoax so I contacted Wolf Singer – another neuroscientist. He reassured me it was for real, an

The past 50 years have seen remarkable advances in the science of medicine. The pharmacological treatments of disorders such as hypertension

The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4-methylenedioxymethamphetamine (MDMA)

Authors Ksenia Cassidy, CJ Healy, Eva Henje and Wendy D’Andrea Published March 20, 2024 Abstract Challenging experiences in ayahuasca...

Pioneering research highlights the potential for treating the symptoms of Premenstrual Dysphoric Disorder (PMDD). Written by Eleanor...

Minorities’ diminished psychedelic returns: Cardio-metabolic health. Race differences remain a critically understudied gap in psychedelic li

Terminal patients are calling for compassionate access to be granted for psilocybin — the psychedelic substance found in fungi known as ‘mag

Read our latest report on why patients experiencing 'Existential Distress' ought to be permitted access to psilocybin-assisted psychotherap